Why the study?
Diabetes mellitus is an escalating pandemic and cardiovascular risk factor, making understanding the pathophysiology and management of diabetic dyslipidaemia essential to developing new therapeutic strategies.
Design
Review
Key result
This review highlights the pathophysiology of diabetic dyslipidaemia and emphasizes that tailored lipid-lowering therapies can reduce cardiovascular risk in patients with diabetes.
Authors
Loading...
May guide individualized lipid management in diabetes; leaves open optimal regimens pending dedicated RCTs.
This review highlights the pathophysiology, biomarkers, and guideline-directed management of diabetic dyslipidaemia to reduce cardiovascular risk.
Thambiah et al. (2021) conducted a review in Diabetic dyslipidaemia. Lipid lowering therapies was evaluated. This review highlights the pathophysiology of diabetic dyslipidaemia and emphasizes that tailored lipid-lowering therapies can reduce cardiovascular risk in patients with diabetes.